<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35259414</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-7549</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>428</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Behavioural brain research</Title>
          <ISOAbbreviation>Behav Brain Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Distinct sex-dependent behavioral responses induced by two positive allosteric modulators of alpha 5 subunit-containing GABA<sub>A</sub> receptors.</ArticleTitle>
        <Pagination>
          <StartPage>113832</StartPage>
          <MedlinePgn>113832</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbr.2022.113832</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0166-4328(22)00100-0</ELocationID>
        <Abstract>
          <AbstractText>Dysregulation of GABAergic neurotransmission has long been implicated in several psychiatric disorders, including schizophrenia, depression, and anxiety disorders. Alpha 5 subunit-containing GABA<sub>A</sub> receptors (α5-GABA<sub>A</sub>R), which are expressed mainly by pyramidal neurons in the hippocampus, have been proposed as a potential target to treat these psychiatric disorders. Here, we evaluated the effects produced by GL-II-73 and SH-053-2'F-R-CH3 (1, 5, and 10 mg/kg), two positive allosteric modulators of α5-GABA<sub>A</sub>R in behavioral tests sensitive to drugs with anxiolytic, antidepressant, and antipsychotic properties in male and female C57BL/6 mice. In both males and females, GL-II-73 produced an anxiolytic-like effect in the elevated plus-maze (EPM) and novelty-suppressed feeding and a rapid and sustained antidepressant-like effect in the forced swim test. GL-II-73 also induced antipsychotic-like effects in males indicated by attenuating MK-801-induced hyperlocomotion and prepulse inhibition (PPI) disruption. However, GL-II-73 per se increased locomotor activity and impaired fear memory extinction in males and females and PPI in males. On the other hand, SH-053-2'F-R-CH3 induced anxiolytic-like effects in the EPM and facilitated fear memory extinction in males. Contrary to GL-II-73, SH-053-2'F-R-CH3 attenuated MK-801-induced hyperlocomotion and PPI disruption in females but not in males. Neither of these drugs induced rewarding effects or impaired motor coordination. These findings suggest that GL-II-73 and SH-053-2'F-R-CH3 cause distinct sex-dependent behavioral responses and support continued preclinical research on the potential of positive allosteric modulators of α5-GABA<sub>A</sub>R for the treatment of psychiatric disorders.</AbstractText>
          <CopyrightInformation>Copyright © 2022. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Souza</LastName>
            <ForeName>Adriana Jesus</ForeName>
            <Initials>AJ</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cortez</LastName>
            <ForeName>Isadora L</ForeName>
            <Initials>IL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silva</LastName>
            <ForeName>Nicole R</ForeName>
            <Initials>NR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pedrazzi</LastName>
            <ForeName>João Francisco C</ForeName>
            <Initials>JFC</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Domingos</LastName>
            <ForeName>Luana B</ForeName>
            <Initials>LB</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Braga</LastName>
            <ForeName>Matheus Silva</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Santos-Silva</LastName>
            <ForeName>Thamyris</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Del-Bel</LastName>
            <ForeName>Elaine A</ForeName>
            <Initials>EA</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Physiology, Ribeirão Preto Dentistry School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Resstel</LastName>
            <ForeName>Leonardo B M</ForeName>
            <Initials>LBM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Guanguan</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, University of Wisconsin Milwaukee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mian</LastName>
            <ForeName>Md Yeunus</ForeName>
            <Initials>MY</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, University of Wisconsin Milwaukee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sharmin</LastName>
            <ForeName>Dishary</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, University of Wisconsin Milwaukee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guimarães</LastName>
            <ForeName>Francisco S</ForeName>
            <Initials>FS</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cook</LastName>
            <ForeName>James M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Chemistry and Biochemistry, University of Wisconsin Milwaukee, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gomes</LastName>
            <ForeName>Felipe V</ForeName>
            <Initials>FV</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology, Ribeirão Preto Medical School, University of São Paulo, Brazil. Electronic address: gomesfv@usp.br.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R01 NS076517</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>05</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Behav Brain Res</MedlineTA>
        <NlmUniqueID>8004872</NlmUniqueID>
        <ISSNLinking>0166-4328</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014151">Anti-Anxiety Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011963">Receptors, GABA-A</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>12794-10-4</RegistryNumber>
          <NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>56-12-2</RegistryNumber>
          <NameOfSubstance UI="D005680">gamma-Aminobutyric Acid</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>6LR8C1B66Q</RegistryNumber>
          <NameOfSubstance UI="D016291">Dizocilpine Maleate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014151" MajorTopicYN="Y">Anti-Anxiety Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014150" MajorTopicYN="Y">Antipsychotic Agents</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016291" MajorTopicYN="N">Dizocilpine Maleate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011963" MajorTopicYN="N">Receptors, GABA-A</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005680" MajorTopicYN="N">gamma-Aminobutyric Acid</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Anxiety</Keyword>
        <Keyword MajorTopicYN="Y">Depression</Keyword>
        <Keyword MajorTopicYN="Y">Excitatory-inhibitory balance</Keyword>
        <Keyword MajorTopicYN="Y">GABA(A) receptors</Keyword>
        <Keyword MajorTopicYN="Y">GL-II-73</Keyword>
        <Keyword MajorTopicYN="Y">SH-053–2′F-R-CH3</Keyword>
        <Keyword MajorTopicYN="Y">Schizophrenia</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>20</Hour>
          <Minute>10</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35259414</ArticleId>
        <ArticleId IdType="doi">10.1016/j.bbr.2022.113832</ArticleId>
        <ArticleId IdType="pii">S0166-4328(22)00100-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
